SCHEMBL6695754

SCHEMBL6695754

N=C(N)Nc1nc(-c2ccccc2)c2cc(Cl)ccc2n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.69
GAA P10253 5/20 0.69
TP53 P04637 1/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
ALDH1A1 P00352 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
ADORA1 P30542 2/20 0.60
KMT2A Q03164 2/20 0.56
POLB P06746 2/20 0.56
RAD52 P43351 1/20 0.56
KDM4E B2RXH2 5/20 0.51
MAT2A P31153 1/20 0.51
THRB P10828 1/20 0.50
MEN1 O00255 1/20 0.49
LMNA P02545 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6696127 0.93 MAPT (0.59) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6694550 0.91 ADORA1 (0.60) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6690817 0.89 MAPT (0.55) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6701160 0.89 MAPT (0.54) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6695182 0.89 HSP90AB1 (0.61) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6701110 0.89 MAPT (0.54) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6699515 0.88 MAPT (0.54) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6693939 0.87 GAA (0.51) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6695601 0.87 MAPT (0.52) MAPTGAATP53SMN1; SMN2ALDH1A1
SCHEMBL6693258 0.86 GAA (0.55) MAPTGAATP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558366-B2 Bacterial DNA gyrase inhibitors and methods of use thereof THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2026-02-24 US disclosed
US-20250090566-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2025-03-20 US disclosed
US-12121528-B2 Bacterial DNA gyrase inhibitors and methods of use thereof THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2024-10-22 US disclosed
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 US disclosed
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2023-11-16 US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 US disclosed
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-05-04 US disclosed
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US disclosed
EP-1274691-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GmbH (DE) 2003-01-15 EP disclosed
WO-2001079186-A1 2-GUANIDINO-4-ARYLCHINAZOLINES AS NHE-3 INHIBITORS MERCK PATENT GMBH (DE) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12121528-B2 Bacterial DNA gyrase inhibitors and methods of use thereof TOP1, DNA2, TOP2A MAPT 3260/4885GAA 433/4885TP53 1815/4885
US-20250090566-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MAPT 3260/4885GAA 433/4885TP53 1815/4885
US-20230364057-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MAPT 3260/4885GAA 433/4885TP53 1815/4885
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors NHERF1, SLC9A3, SLC9A1 MAPT 4292/4885GAA 666/4885TP53 3706/4885
US-20230136466-A1 BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF TOP1, DNA2, TOP2A MAPT 3260/4885GAA 433/4885TP53 1815/4885
US-12558366-B2 Bacterial DNA gyrase inhibitors and methods of use thereof DNA2, TOP2A, TOP2B MAPT 1868/4885GAA 652/4885TP53 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.